NCT02261532View on ClinicalTrials.gov

A Phase I Study of TAS-102 in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

June 30, 2017

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

TAS-102

TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Trial Locations (1)

Unknown

Taiho Pharmaceutical Co., Ltd selected site, Beijing

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT02261532 - A Phase I Study of TAS-102 in Solid Tumors | Biotech Hunter | Biotech Hunter